72834 Federal Register / Vol. 75, No. 227 / Friday, November 26, 2010 / Notices 

Time: 8:30 a.m. to 5 p.m. 

Agenda: Presentation and discussion will 

include recommendations from the 

Translational Medicine and Therapeutics 

working group and the Intramural Research 

Program working group. Any supporting 

documentation for this meeting, including 

the agenda, will be available at http:// 

smrb.od.nih.gov. Sign up for public comment 

will begin at approximately 7:30 a.m. on 

December 7 and will be restricted to one sign 

in per person. In the event that time does not 

allow for all those interested to present oral 

comments, anyone may file written 

comments using the contact person’s address 

below. 

Place: National Institutes of Health, 

Building 31, 6th Floor, Conference Room 6, 

31 Center Drive, Bethesda, MD 20892. 

Contact Person: Lyric Jorgenson, Office of 

Science Policy, Office of the Director, NIH, 

National Institutes of Health, 6705 Rockledge 

Drive, Suite 750, Bethesda, MD 20892. 

smrb@mail.nih.gov. (301) 496–6837. 

This meeting is being published less than 

15 days prior to the meeting due to 

scheduling conflicts of the Members. 

Any interested person may file written 

comments with the committee by forwarding 

the statement to the Contact Person listed on 

this notice. The statement should include the 

name, address, telephone number and when 

applicable, the business or professional 

affiliation of the interested person. 

In the interest of security, NIH has 

instituted stringent procedures for entrance 

onto the NIH campus. All visitor vehicles, 

including taxicabs, hotel, and airport shuttles 

will be inspected before being allowed on 

campus. Visitors will be asked to show one 

form of identification (for example, a 

government-issued photo ID, driver’s license, 

or passport) and to state the purpose of their 

visit. 

The meeting will also be Webcast. The 

draft meeting agenda and other information 

about the SMRB, including information about 

access to the Webcast, will be available at 

http://smrb.od.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.14, Intramural Research 

Training Award; 93.22, Clinical Research 

Loan Repayment Program for Individuals 

from Disadvantaged Backgrounds; 93.232, 

Loan Repayment Program for Research 

Generally; 93.39, Academic Research 

Enhancement Award; 93.936, NIH Acquired 

Immunodeficiency Syndrome Research Loan 

Repayment Program; 93.187, Undergraduate 

Scholarship Program for Individuals from 

Disadvantaged Backgrounds, National 

Institutes of Health, HHS) 

Dated: November 19, 2010. 

Jennifer S. Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2010–29748 Filed 11–24–10; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Food and Drug Administration 

[Docket No. FDA–2010–N–0001] 

Blood Products Advisory Committee; 

Notice of Meeting 

AGENCY: Food and Drug Administration, 

HHS. 

ACTION: Notice. 

This notice announces a forthcoming 

meeting of a public advisory committee 

of the Food and Drug Administration 

(FDA). At least one portion of the 

meeting will be closed to the public. 

Name of Committee: Blood Products 

Advisory Committee. 

General Function of the Committee: 

To provide advice and 

recommendations to the Agency on 

FDA’s regulatory issues. 

Date and Time: The meeting will be 

held on December 14, 2010, from 8 a.m. 

to approximately 5:30 p.m. and on 

December 15, 2010, from 8 a.m. to 

approximately 12:45 p.m. 

Location: Hilton Washington DC/ 

North, 620 Perry Pkwy., Gaithersburg, 

MD. 

Contact Person: Bryan Emery or 

Pearline Muckelvene, Center for 

Biologics Evaluation and Research, 

Food and Drug Administration (HFM– 

71), 1401 Rockville Pike, Rockville, MD 

20852, 301–827–0314, or FDA Advisory 

Committee Information Line, 1–800– 

741–8138 (301–443–0572 in the 

Washington, DC area), code 

3014519516. Please call the Information 

Line for up-to-date information on this 

meeting. A notice in the Federal 

Register about last minute modifications 

that impact a previously announced 

advisory committee meeting cannot 

always be published quickly enough to 

provide timely notice. Therefore, you 

should always check the Agency’s Web 

site and call the appropriate advisory 

committee hot line/phone line to learn 

about possible modifications before 

coming to the meeting. 

Agenda: On December 14, 2010, in 

the morning, the committee will discuss 

the risk of dengue virus infection in 

blood donors. In the afternoon, the 

committee will discuss murine 

leukemia virus-related human 

retroviruses and blood safety. On 

December 15, 2010, in the morning, the 

committee will hear updates on the 

following topics: (1) November 4 and 5, 

2010, meeting of the Health and Human 

Services Advisory Committee on Blood 

Safety and Availability and (2) 

December 9 and 10, 2010, FDA 

workshop entitled ‘‘Product 

Development Program for Interventions 

in Patients With Severe Bleeding Due to 

Trauma and Other Causes,’’ and (3) 

Research programs in the Laboratories 

of Hemostasis and Plasma Derivatives, 

Division of Hematology, Office of Blood 

Research and Review, Center for 

Biologics Evaluation and Research. 

FDA intends to make background 

material available to the public no later 

than 2 business days before the meeting. 

If FDA is unable to post the background 

material on its Web site prior to the 

meeting, the background material will 

be made publicly available at the 

location of the advisory committee 

meeting, and the background material 

will be posted on FDA’s Web site after 

the meeting. Background material is 

available at http://www.fda.gov/ 

AdvisoryCommittees/Calendar/ 

default.htm. Scroll down to the 

appropriate advisory committee link. 

Procedure: On December 14, from 8 

a.m. to 5:30 p.m. the meeting is open to 

the public. On December 15, from 8 a.m. 

to 12 noon the meeting is open to the 

public. Interested persons may present 

data, information, or views, orally or in 

writing, on issues pending before the 

committee. Written submissions may be 

made to the contact person on or before 

December 7, 2010. Oral presentations 

from the public will be scheduled 

between approximately 10:15 a.m. and 

11 a.m. and between 3:45 p.m. and 4:15 

p.m. on December 14, 2010, and 

between approximately 11:30 a.m. and 

12 noon on December 15, 2010. Those 

individuals interested in making formal 

oral presentations should notify the 

contact person and submit a brief 

statement of the general nature of the 

evidence or arguments they wish to 

present, the names and addresses of 

proposed participants, and an 

indication of the approximate time 

requested to make their presentation on 

or before November 29, 2010. Time 

allotted for each presentation may be 

limited. If the number of registrants 

requesting to speak is greater than can 

be reasonably accommodated during the 

scheduled open public hearing session, 

FDA may conduct a lottery to determine 

the speakers for the scheduled open 

public hearing session. The contact 

person will notify interested persons 

regarding their request to speak by 

November 30, 2010. 

Closed Committee Deliberations: On 

December 15, from 12 noon to 12:45 

p.m., the meeting will be closed to 

permit discussion where disclosure 

would constitute a clearly unwarranted 

invasion of personal privacy (5 U.S.C. 

552b(c)(6)). The committee will discuss 

reports of intramural research programs 


srobinson on DSKHWCL6B1PROD with NOTICES
Federal Register / Vol. 75, No. 227 / Friday, November 26, 2010 / Notices 72835 

and make recommendations regarding 

personnel staffing decisions. 

Persons attending FDA’s advisory 

committee meetings are advised that the 

Agency is not responsible for providing 

access to electrical outlets. 

FDA welcomes the attendance of the 

public at its advisory committee 

meetings and will make every effort to 

accommodate persons with physical 

disabilities or special needs. If you 

require special accommodations due to 

a disability, please contact Bryan Emery 

at least 7 days in advance of the 

meeting. 

FDA is committed to the orderly 

conduct of its advisory committee 

meetings. Please visit our Web site at 

http://www.fda.gov/ 

AdvisoryCommittees/ 

AboutAdvisoryCommittees/ 

ucm111462.htm for procedures on 

public conduct during advisory 

committee meetings. 

Notice of this meeting is given under 

the Federal Advisory Committee Act (5 

U.S.C. app. 2). 

Dated: November 19, 2010. 

Thinh Nguyen, 

Acting Associate Commissioner for Special 

Medical Programs. 

[FR Doc. 2010–29818 Filed 11–24–10; 8:45 am] 

BILLING CODE 4160–01–P 

DEPARTMENT OF HOUSING AND 

URBAN DEVELOPMENT 

[Docket No. FR–5375–N–46] 

Federal Property Suitable as Facilities 

To Assist the Homeless 

AGENCY: Office of the Assistant 

Secretary for Community Planning and 

Development, HUD. 

ACTION: Notice. 

SUMMARY: This Notice identifies 

unutilized, underutilized, excess, and 

surplus Federal property reviewed by 

HUD for suitability for possible use to 

assist the homeless. 

DATES: Effective Date: November 26, 

2010. 

FOR FURTHER INFORMATION CONTACT: 

Kathy Ezzell, Department of Housing 

and Urban Development, 451 Seventh 

Street, SW., Room 7262, Washington, 

DC 20410; telephone (202) 708–1234; 

TTY number for the hearing- and 

speech-impaired (202) 708–2565, (these 

telephone numbers are not toll-free), or 

call the toll-free Title V information line 

at 800–927–7588. 

SUPPLEMENTARY INFORMATION: In 

accordance with the December 12, 1988 

court order in National Coalition for the 

Homeless v. Veterans Administration, 

No. 88–2503–OG (D.D.C.), HUD 

publishes a Notice, on a weekly basis, 

identifying unutilized, underutilized, 

excess and surplus Federal buildings 

and real property that HUD has 

reviewed for suitability for use to assist 

the homeless. Today’s Notice is for the 

purpose of announcing that no 

additional properties have been 

determined suitable or unsuitable this 

week. 

Dated: November 18, 2010. 

Mark R. Johnston, 

Deputy Assistant Secretary for Special Needs. 

[FR Doc. 2010–29535 Filed 11–23–10; 8:45 am] 

BILLING CODE 4210–67–P 

DEPARTMENT OF THE INTERIOR 

National Park Service 

[2275–669] 

Proposed Information Collection; OMB 

Control Number 1024–0037 

AGENCY: National Park Service, Interior. 

ACTION: Notice; request for comments. 

SUMMARY: We (National Park Service) 

will ask the Office of Management and 

Budget (OMB) to approve the 

information collection (IC) described 

below. As required by the Paperwork 

Reduction Act of 1995 and 5 CFR part 

1320, Reporting and Record Keeping 

Requirements, and as part of our 

continuing efforts to reduce paperwork 

and respondent burden, we invite the 

general public and other Federal 

agencies to take this opportunity to 

comment on this information collection. 

This IC is scheduled to expire on April 

30, 2011. We may not conduct or 

sponsor, and a person is not required to 

respond to, a collection of information 

unless it displays a currently valid OMB 

control number. 

DATES: To ensure we are able to 

consider your comments on this IC, we 

must receive them by January 25, 2011. 

ADDRESSES: Send comments to Daniel 

Odess, Acting Manager, Archeology 

Program, National Park Service, 1849 C 

Street, NW., (2275), Washington, DC 

20240. Phone: 202–354–2128; Fax: 202– 

371–5102; or by e-mail at 

mailto:daniel_odess@nps.gov. You may 

also send comments to Robert Gordon, 

Information Collection Clearance 

Officer, National Park Service, 1201 Eye 

Street NW., (MS 1237), Washington, DC 

20005 (mail); or robert_gordon@nps.gov 

(e-mail). 

FOR FURTHER INFORMATION CONTACT: To 

request additional information about 

this IC, contact David Gadsby, 

Archeology Program, National Park 

Service, 1849 C Street, NW., (2275), 

Washington, DC 20240. Phone: 202– 

354–2101; Fax: 202–371–5102; or by email at david_gadsby@nps.gov. You may 

also contact Robert Gordon by mail or 

e-mail (see ADDRESSES) or by telephone 

at 202–354–1936. 

SUPPLEMENTARY INFORMATION: 

I. Abstract 

Section 4 of the Archeological 

Resources Protection Act (ARPA) of 

1979 (16 U.S.C 470cc), and Section 3 of 

the Antiquities Act (AA) of 1906 (16 

U.S.C. 432), authorize any individual or 

institution to apply to Federal land 

managing agencies to scientifically 

excavate or remove archeological 

resources from public or Indian lands. 

43 CFR part 7 for ARPA, and 43 CFR 

part 3 for the AA, ensure that the 

resources are scientifically excavated or 

removed and deposited, along with 

associated records, in a suitable 

repository for preservation. Section 13 

of ARPA (16 U.S.C. 470ll) requires that 

the Secretary of the Interior report 

annually to the Congress on 

archeological activities conducted 

pursuant to the Act. The information 

collected is reported periodically to 

Congress and is used for land 

management purposes. The obligation to 

respond is required to obtain or retain 

benefits. 

II. Data 

OMB Control Number: 1024–0037. 

Title: Archeology Permits and 

Reports—43 CFR parts 3 and 7. 

Service Form Number(s): DI–1926 

(permit application) 

Type of request: Extension of a 

currently approved information 

collection. 

Description of Respondents: 

Individuals or organizations wishing to 

excavate or remove archeological 

resources from public or Indian lands. 

Respondent’s Obligation: Mandatory. 

Frequency of Collection: On occasion. 

Estimated average number of 

respondents: 736 per year. 

Estimated average number of 

responses: 1472 per year (2 per 

respondent). 

Estimated average time burden per 

response: 3 hours. 

Estimated total annual reporting 

burden: 2,208 hours. 

Estimated Annual Nonhour Burden 

Cost: Not Applicable. 

III. Comments 

We invite comments on: 

• The practical utility of the 

information being gathered; 


srobinson on DSKHWCL6B1PROD with NOTICES